Mednet Logo
HomeDermatologyQuestion

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?

2
3 Answers
Mednet Member
Mednet Member
Dermatology · Icahn School of Medicine at Mount Sinai (Elmhurst)

I have had good success with both deucravacitinib and bimekizumab and these agents are two welcome additions to our psoriasis treatment arsenal.

For deucravacitinib, ever since I included it in my list of options in treating psoriasis - as an aside, I used to skip over orals due to lack of efficacy ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Dermatology · Wake Forest University

I’ve begun treating patients with both deucravacitinib and bimekizumab. I tend to prescribe deucravacitinib to patients who prefer oral treatment and who don’t mind the slight herpes simplex/zoster signal associated with the drug. I also use it for patients who have failed multiple biologic treatmen...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Dermatology · University of Pennsylvania Perelman School of Medicine

I have an unusual practice as I treat very severe psoriasis in patients who typically have failed multiple treatments. I've had great success with bimekizumab in some of my hardest-to-treat patients who have failed literally everything else. The question now is, will these patients continue to respo...

Register or Sign In to see full answer

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments? | Mednet